MaxCyte Inc's (LON:MXCT) technology may have a role to play in the treatment of sickle cell disease (SCD).
Pre-clinical data presented Friday (May 18) at an industry assessed the use of non-viral CRISPR-mediated gene-correction in the treatment of the blood disorder.
The data from work with the National Institutes of Health's National Heart Lung and Blood Institute demonstrated the potential of MaxCyte's technologies and the non-viral CRISPR gene correction in the treatment of SCD.
Delegates at the American Society of Gene and Cell Therapy, held in Chicago, were provided the information in a poster.
The company's chief executive, Doug Doerfler, said: "We're encouraged that MaxCyte's technology is at the forefront of enabling non-viral CRISPR-mediated correction of disease mutations at clinically-relevant levels.
"We're excited by these results for their potential to bring therapeutic benefit to individuals living with SCD."